Role of serum IL-26 in Pathogenesis of Psoriasis vulgaris

Document Type : Original Article

Authors

1 microbiology and immunology department, Faculty of Medicine, Suez University, Suez, Egypt

2 Dermatology department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt

3 microbiology and immunology department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt

Abstract

Background: Systemic inflammation and thick, red, scaly plaques on the skin characterize psoriasis vulgaris, which is  a common and varied chronic inflammatory dermatological disorder. IL-26 has been categorized as both an IL-10 family member and an IL-20 subfamily member. This cytokine was first found in T cells that had been modified by the herpesvirus saimiri. Aim of the work: We want to learn more about the relationship between IL-26 levels and the severity of psoriasis by comparing the serum and tissue IL-26 levels of people with psoriasis to those of a healthy control group. Patients and Methods: This study was a case-control research that took place between March 2021 and September 2021 at the Beni-Suef University Hospital Dermatology outpatient clinic. Twenty men and ten females with psoriasis participated in the research, which was approved by the Research Ethics Committee (REC). Patients' ages varied widely, from 28 to 50, with a mean (standard deviation) of (42.50 ±6.5) years. Thirty people who did not have psoriasis (healthy controls) participated in the research. In terms of age and sex, these controls were excellent analogs for the psoriasis patients. Every individual who took part in the study had their whole medical and personal history compiled. The IL-26 Human ELISA kit was used to analyze the concentration of IL-26 in the blood and their expression in tissues. Results: In contrast to the control group of healthy people, those with a psoriasis diagnosis were shown to have significantly higher levels of serum IL-26 and tissue expression. Clinical psoriasis severity, as measured by the Psoriasis Area and Severity Index (PASI) score, was shown to be positively correlated with both the blood level and tissue expression of IL-26. Serum IL-26 concentration was positively and statistically significantly related to Psoriasis disease severity and duration. Serum and tissue levels were not associated with age, gender, family history, onset, or progression of illness in patients. Conclusion: IL-26 may be related to the severity of psoriasis and plays a crucial part in the disease's development. Our research looks at how Interleukin-26 (IL-26) plays a part in the development of psoriasis by analyzing its expression in both tissue and serum samples.

Keywords

Main Subjects

References

  1. Boehncke, W. H., & Schön, M. P. Psoriasis. Lancet [Internet]. 2015; 386 (9997): 983–94.‏
  2. Furue, M., Yamazaki, S., Jimbow, K., Tsuchida, T., Amagai, M., Tanaka, T., ... & Manabe, M. (2011). Prevalence of dermatological disorders in Japan: a nationwide, cross‐sectional, seasonal, multicenter, hospital‐based study. The Journal of dermatology, 38(4), 310-320.‏
  3. Hägg, D., Eriksson, M., Sundström, A., & Schmitt-Egenolf, M. (2013). The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PloS one, 8(5), e63619.‏
  4. Rachakonda, T. D., Schupp, C. W., & Armstrong, A. W. (2014). Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, 70(3), 512-516.‏
  5. Na, S. J., Jo, S. J., & Youn, J. I. (2013). Clinical study on psoriasis patients for past 30 years (1982–2012) in S eoul N ational U niversity H ospital P soriasis C linic. The Journal of dermatology, 40(9), 731-735.‏
  6. Bilovol, A., Berehova, A., Tkachenko, S., Tatuzian, E., & Havryliuk, O. (2019). Venereology. Part 2: textbook for 4-year dentistry students.‏
  7. Hawkes E. J , Chan T. C., and Krueger G. J.2017. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017 ;140(3):645-653. doi: 10.1016/j.jaci.2017.07.004.
  8. Tokuyama, M., & Mabuchi, T. (2020). New treatment addressing the pathogenesis of psoriasis. International Journal of Molecular Sciences, 21(20), 7488
  9. Batycka-Baran, A., Maj, J., Wolf, R., & Szepietowski, J. C. (2014). The new insight into the role of antimicrobial proteins-alarmins in the immunopathogenesis of psoriasis. Journal of immunology research, 2014.‏
  10. Corvaisier, M., Delneste, Y., Jeanvoine, H., Preisser, L., Blanchard, S., Garo, E., ... & Jeannin, P. (2012). IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation.‏ PLoS Biol. 2012. ;10(9):e1001395.doi: 10.1371/journal.pbio.1001395.
  11. Ohnuma, K., Hatano, R., Aune, T. M., Otsuka, H., Iwata, S., Dang, N. H., ... & Morimoto, C. (2015). Regulation of pulmonary graft-versus-host disease by IL-26+ CD26+ CD4 T lymphocytes. The Journal of Immunology, 194(8), 3697-3712.‏
  12. Caiazzo, G., Di Caprio, R., Lembo, S., Raimondo, A., Scala, E., Patruno, C., & Balato, A. (2018). IL‐26 in allergic contact dermatitis: Resource in a state of readiness. Experimental dermatology, 27(6), 681-684.‏
  13. Itoh, T., Hatano, R., Komiya, E., Otsuka, H., Narita, Y., Aune, T. M., ... & Ohnuma, K. (2019). Biological Effects of IL-26 on T Cell–Mediated Skin Inflammation, Including Psoriasis. Journal of Investigative Dermatology, 139(4), 878-889.‏
  14. Mahil, S. K., & Smith, C. H. (2019). Psoriasis biologics: a new era of choice. Lancet, 394(10201), 807-8.‏
  15. Mehrmal, S., Uppal, P., Nedley, N., Giesey, R. L., & Delost, G. R. (2021). The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017. Journal of the American Academy of Dermatology, 84(1), 46-52.‏
  16. Gowhari Shabgah, A., Abdelbasset, W. K., Sulaiman Rahman, H., Bokov, D. O., Suksatan, W., Thangavelu, L., ... & Gholizadeh Navashenaq, J. (2022). A comprehensive review of IL‐26 to pave a new way for a profound understanding of the pathobiology of cancer, inflammatory diseases and infections. Immunology, 165(1), 44-60.‏
  17. Wilson, N. J., Boniface, K., Chan, J. R., McKenzie, B. S., Blumenschein, W. M., Mattson, J. D., ... & de Waal Malefyt, R. (2007). Development, cytokine profile and function of human interleukin 17–producing helper T cells. Nature immunology, 8(9), 950-957.‏
  18. Heidenreich, R., Röcken, M., & Ghoreschi, K. (2009). Angiogenesis drives psoriasis pathogenesis. International journal of experimental pathology, 90(3), 232-248.‏
  19. Scala, E., Di Caprio, R., Cacciapuoti, S., Caiazzo, G., Fusco, A., Tortorella, E., ... & Balato, A. (2019). A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin‐British Journal of Dermatology, 181(5), 1038-1045.‏
  20. Caprio, R. D., Balato, A., Caiazzo, G., Scala, E., Raimondo, A., Romanelli, M., & Chiricozzi, A. (2018,). The effects of skin psoriasis inflammation on adipose tissue-derived mediators and viceversa. In EXPERIMENTAL DERMATOLOGY(Vol. 27, pp. 19-19).
Egyptian Journal of Medical Research
Volume 4, Issue 4
October 2023
Pages 105-116

Files

Share

How to cite

Statistics